Lipitor Topped Worldwide Drug Sales in 2010; Crestor Gains Most

The following table ranks the top 15 prescription drugs sold by pharmaceutical and biotechnology companies in 2010 and shows year-over-year sales comparisons. The rankings are based on data from company figures. Sales of drugs sold by multiple companies are combined. All figures are in U.S. dollars. Foreign currency exchange rates were based on the average annual swap price.

Drug Name Used For Company 2010 SALES Y-O-Y Rank

(BLN US$) Change ================================================================ 1. Lipitor High Pfizer 10.7 -6%

cholesterol

2. Plavix Blood clot Bristol-Myers/ 9.43 -4%

prevention Sanofi-Aventis

3. Remicade Rheumatoid J&J/Merck & Co./ 7.99 N/A

arthritis/ Mitsubishi Tanabe

Psoriasis/

Crohn’s disease 4. Advair/ Asthma GlaxoSmithKline 7.94 2%

Seretide

5. Enbrel Rheumatoid Amgen/Pfizer 7.23 N/A

arthritis/ Takeda

Psoriasis

6. Abilify Depression/ Otsuka/ 6.78* N/A

Bipolar Bristol-Myers

disorder/

Schizophrenia

7. Humira Rheumatoid Abbott 6.55 19%

arthritis/

Psoriasis/

Crohn’s disease

8. Avastin Cancer Roche 6.22 8%

9. Rituxan/ Lymphoma/ Roche/Biogen Idec 6.11 9%

Mabthera Leukemia

10. Diovan High blood Novartis 6.05 1%

pressure

11. Crestor High AstraZeneca 5.69 26%

cholesterol

12. Seroquel Depression/ AstraZeneca 5.3 9%

Bipolar

disorder/

Schizophrenia

13. Herceptin Breast Roche 5.22 7%

cancer

14. Zyprexa Bipolar Eli Lilly 5.03 2%

disorder/

Schizophrenia

15. Singulair Asthma/ Merck & Co. 4.99 7%

Allergies

*Estimated, Otsuka declined to provide 2010 sales. Some year- over-year sales comparisons are N/A because there isn’t comparable 2009 data.

To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.